blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4294843

EP4294843 - COMPOSITIONS COMPRISING 4-1BB AND OX40 BINDING PROTEINS AND METHODS OF USE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  24.11.2023
Database last updated on 11.09.2024
FormerThe international publication has been made
Status updated on  26.08.2022
Formerunknown
Status updated on  24.03.2022
Most recent event   Tooltip19.04.2024Change: Validation statespublished on 22.05.2024  [2024/21]
19.04.2024Change - extension statespublished on 22.05.2024  [2024/21]
Applicant(s)For all designated states
Aptevo Research and Development LLC
2401 4th Avenue
Suite 1050
Seattle, WA 98121 / US
[2023/52]
Inventor(s)01 / BIENVENUE, David Leonard
Seattle, Washington 98121 / US
 [2023/52]
Representative(s)FRKelly
Waterways House
Grand Canal Quay
Dublin D02 PD39 / IE
[N/P]
Former [2023/52]FRKelly
27 Clyde Road
Dublin D04 F838 / IE
Application number, filing date22710217.517.02.2022
[2023/52]
WO2022US16776
Priority number, dateUS202163150475P17.02.2021         Original published format: US 202163150475 P
[2023/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022178114
Date:25.08.2022
Language:EN
[2022/34]
Type: A1 Application with search report 
No.:EP4294843
Date:27.12.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 25.08.2022 takes the place of the publication of the European patent application.
[2023/52]
Search report(s)International search report - published on:EP25.08.2022
ClassificationIPC:C07K16/28, A61P35/00
[2023/52]
CPC:
C07K16/2878 (EP,KR,US); A61K39/39591 (KR,US); A61K47/183 (KR,US);
A61K47/20 (KR); A61K47/26 (KR,US); A61K9/08 (KR);
A61P35/00 (EP,KR); A61K2039/505 (EP,KR); C07K2317/31 (EP,KR,US);
C07K2317/522 (EP,KR); C07K2317/622 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/52]
TitleGerman:ZUSAMMENSETZUNGEN MIT 4-1BB- UND OX40-BINDENDEN PROTEINEN UND VERFAHREN ZUR VERWENDUNG[2023/52]
English:COMPOSITIONS COMPRISING 4-1BB AND OX40 BINDING PROTEINS AND METHODS OF USE[2023/52]
French:COMPOSITIONS COMPRENANT DES PROTÉINES DE LIAISON À 4-1BB ET OX40 ET LEURS PROCÉDÉS D'UTILISATION[2023/52]
Entry into regional phase22.08.2023National basic fee paid 
22.08.2023Designation fee(s) paid 
22.08.2023Examination fee paid 
Examination procedure22.08.2023Examination requested  [2023/52]
22.08.2023Date on which the examining division has become responsible
08.04.2024Amendment by applicant (claims and/or description)
Fees paidRenewal fee
09.01.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]US2018118841  (ELLMARK PETER [SE], et al) [I] 1-65* paragraphs [0001] , [0010] - [0017] - [0 28] , [0126] , [0127] , [0138] - [0147] - [0206] - [0218] - [0605] - [0610]; example 14 *;
 [I]WO2020011966  (F STAR BETA LTD [GB]) [I] 1-65 * page 52, line 27 - page 53, line 19 * * page 1, lines 3-7 * * page 7, line 5 - page 12, line 34 * * page 55, line 1 - page 56, line 23 *;
 [A]WO2020150496  (COMPASS THERAPEUTICS LLC [US]) [A] 1-65 * page 3, paragraph 2 - page 4, paragraph 1 * * page 4, paragraph 2 - page 14, paragraph 5 * * page 47, paragraph 2 - page 51, paragraph 3 * * page 87, paragraph 2 - page 111, paragraph 1 *;
 [XP]WO2021030488  (BIENVENUE DAVID LEONARD [US], et al) [XP] 32-34 * paragraphs [0085] - [0093] - [0193] - [0198] - [0384] - [0391]; sequences 17,18,30,31 *;
 [A]  - WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505 [A] 1-65 * page 15, column r, paragraph 2 - page 17, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1002/jps.20727
 [A]  - MIGUEL GASPAR ET AL, "CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement", CANCER IMMUNOLOGY RESEARCH, US, (20200409), vol. 8, no. 6, doi:10.1158/2326-6066.CIR-19-0798, ISSN 2326-6066, pages 781 - 793, XP055740060 [A] 1-65 * the whole document *

DOI:   http://dx.doi.org/10.1158/2326-6066.CIR-19-0798
by applicantUS5225539
 US2013095097
 US2013129723
    - YE et al., Oncolmmunology, (20130000), vol. 2, page e27184
    - MONTLER et al., Clin Transl Immunology, (20160000), vol. 5, page e70
    - CHESTER et al., Blood, (20180000), vol. 131, pages 39 - 57
    - OHSIMA et al., J. Immunology, (19970000), vol. 159, pages 3838 - 3848
    - IMURA et al., J. Exp. Med., (19960000), vol. 183, pages 2185 - 2195
    - MAXWELL et al., J. Immunology, (20000000), vol. 164, pages 107 - 112
    - GOUGH et al., J. Immunotherapy, (20100000), vol. 33, no. 8, pages 798 - 809
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327
    - VERHOEYEN et al., Science, vol. 239, pages 1534 - 1536
    - ROGUSKA et al., Proc. Natl. Acad. Sci., USA, (19940000), vol. 91, no. 3, pages 969 - 973
    - ROGUSKA et al., Protein Eng., (19960000), vol. 9, no. 10, pages 895 - 904
    - KABAT EAWU TT, Ann NY Acad Sci, (19710000), vol. 190, pages 382 - 391
    - CHOTHIALESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - BROCHET, X et al., Nucl. Acids Res, (20080000), vol. 36, pages W503 - 508
    - PUTNAM, The Plasma Proteins, Academic Press, (19870000), vol. V, pages 49 - 140
    - PADLAN, Mol. Immunol., (19940000), vol. 31, pages 169 - 217
    - EDELMAN, G.M. et al., Proc. Natl. Acad. USA, (19690000), vol. 63, pages 78 - 85
    - WARD et al., Therap. Immunol., (19950000), vol. 2, pages 77 - 94
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.